Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ENPP1 inhibitor RBS2418

A selective small molecule inhibitor of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), with potential immunomodulating and antineoplastic activities. Upon administration, ENPP1 inhibitor RBS2418 targets and binds to ENPP1, thereby inhibiting the activity of ENPP1. This inhibits ENPP1-mediated 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) and adenosine triphosphate (ATP) hydrolysis and stabilizes extracellular endogenous cGAMP and ATP. This leads to the extracellular accumulation of cGAMP and ATP, and inhibits the production of immunosuppressive adenosine in the tumor microenvironment (TME). This allows for induction of anticancer immune responses. ENPP1, overexpressed in a number of tumor types, mediates nucleotide recycling by breaking down ATP to AMP, which is then converted to adenosine. It suppresses anti-tumor immune responses and increases metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:RBS 2418
RBS-2418
RBS2418
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search